Price to Sales (P/S)
since 2005
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Regeneron Pharmaceuticals Inc., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Revenues1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 5, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 5, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 8, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 8, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 12, 2007 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.
The Price-to-Sales (P/S) ratio for the analyzed period exhibits considerable fluctuation, though certain patterns emerge. Initially, the ratio demonstrates volatility, peaking at 19.70 in 2007 before declining significantly to 5.17 in 2009. Following this, a period of moderate increase is observed, reaching a high of 20.90 in 2012. Subsequently, the ratio generally decreased until 2018, before experiencing another increase, peaking at 7.84 in 2023. The most recent values indicate a slight decrease in 2024 and 2025.
- Initial Volatility (2006-2009)
- The period between 2006 and 2009 is characterized by substantial shifts in the P/S ratio. The initial value of 14.06 in 2006 increased to nearly 20 in 2007, then experienced a dramatic decline to 5.17 in 2009. This suggests significant changes in investor expectations relative to sales during this timeframe, potentially influenced by broader economic conditions or company-specific developments.
- Growth and Subsequent Decline (2010-2018)
- From 2010 to 2012, the P/S ratio increased substantially, reaching its highest point in the analyzed period at 20.90. This indicates a period of strong investor confidence and potentially high growth expectations. However, from 2013 through 2018, the ratio generally trended downward, settling at 5.92. This suggests a recalibration of investor sentiment, possibly due to maturing growth rates or increased competition.
- Recent Fluctuations (2019-2025)
- The period from 2019 to 2025 shows continued fluctuation. The ratio remained relatively stable between 5.34 and 7.84. The most recent data points suggest a slight downward trend, with the ratio decreasing from 7.84 in 2023 to 5.71 in 2026. This could indicate emerging concerns about future sales growth or a shift in market valuation.
- Relationship to Sales per Share
- The P/S ratio’s movements are closely linked to changes in sales per share. Periods of increasing sales per share generally coincide with increases in the P/S ratio, and vice versa. However, the relationship is not always direct, suggesting that investor sentiment and broader market factors also play a significant role in determining the ratio’s value.
Overall, the P/S ratio demonstrates a dynamic pattern over the analyzed period, reflecting changes in investor expectations, sales performance, and potentially broader market conditions. The ratio’s fluctuations suggest that the company’s valuation has been subject to periodic reassessment by investors.
Comparison to Competitors
Regeneron Pharmaceuticals Inc., P/S, long-term trends, comparison to competitors
| Regeneron Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | ||||||||||||
| Feb 5, 2025 | ||||||||||||
| Feb 5, 2024 | ||||||||||||
| Feb 6, 2023 | ||||||||||||
| Feb 7, 2022 | ||||||||||||
| Feb 8, 2021 | ||||||||||||
| Feb 7, 2020 | ||||||||||||
| Feb 7, 2019 | ||||||||||||
| Feb 8, 2018 | ||||||||||||
| Feb 9, 2017 | ||||||||||||
| Feb 11, 2016 | ||||||||||||
| Feb 12, 2015 | ||||||||||||
| Feb 13, 2014 | ||||||||||||
| Feb 15, 2013 | ||||||||||||
| Feb 21, 2012 | ||||||||||||
| Feb 17, 2011 | ||||||||||||
| Feb 18, 2010 | ||||||||||||
| Feb 26, 2009 | ||||||||||||
| Feb 27, 2008 | ||||||||||||
| Mar 12, 2007 | ||||||||||||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Regeneron Pharmaceuticals Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Regeneron Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 4, 2026 | ||
| Feb 5, 2025 | ||
| Feb 5, 2024 | ||
| Feb 6, 2023 | ||
| Feb 7, 2022 | ||
| Feb 8, 2021 | ||
| Feb 7, 2020 | ||
| Feb 7, 2019 | ||
| Feb 8, 2018 | ||
| Feb 9, 2017 | ||
| Feb 11, 2016 | ||
| Feb 12, 2015 | ||
| Feb 13, 2014 | ||
| Feb 15, 2013 | ||
| Feb 21, 2012 | ||
| Feb 17, 2011 | ||
| Feb 18, 2010 | ||
| Feb 26, 2009 | ||
| Feb 27, 2008 | ||
| Mar 12, 2007 | ||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Regeneron Pharmaceuticals Inc., P/S, long-term trends, comparison to industry (health care)
| Regeneron Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Feb 4, 2026 | ||
| Feb 5, 2025 | ||
| Feb 5, 2024 | ||
| Feb 6, 2023 | ||
| Feb 7, 2022 | ||
| Feb 8, 2021 | ||
| Feb 7, 2020 | ||
| Feb 7, 2019 | ||
| Feb 8, 2018 | ||
| Feb 9, 2017 | ||
| Feb 11, 2016 | ||
| Feb 12, 2015 | ||
| Feb 13, 2014 | ||
| Feb 15, 2013 | ||
| Feb 21, 2012 | ||
| Feb 17, 2011 | ||
| Feb 18, 2010 | ||
| Feb 26, 2009 | ||
| Feb 27, 2008 | ||
| Mar 12, 2007 | ||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).